Streetbeat News

Products Services

BITC

BITW

GBTC

The SEC remains cautious about approving a Spot Price Bitcoin ETF due to market manipulation concerns. Despite this, several ETFs and investment vehicles have emerged to provide investors with exposure to cryptocurrencies, including Grayscale Bitcoin Trust (OTC:GBTC), Purpose Bitcoin ETF (BTCC), VanEck Vectors Bitcoin Strategy ETF, Bitwise 10 Crypto Index Fund (OTC:BITW), CoinShares Physical Bitcoin (NYSE:BITC), and 3iQ CoinShares Bitcoin ETF.

Portfolio Pulse from Jeffrey Kamys

May 22, 2023 | 2:25 pm

CVX

META

MU

UBER

XOM

Meta faces a record $1.3B penalty for data privacy violation, Uber's diversity leader is suspended amid racism complaints, and China bans some of Micron's product sales. Exxon explores lithium production, and Chevron acquires PDC Energy in a $7.6B deal.

Portfolio Pulse from Vandana Singh

May 22, 2023 | 2:21 pm

BA

ESYJY

EXPE

RYAAY

Ryanair reported a near-record annual profit of €1.4 billion, bouncing back from a €355m loss the previous year. The company has spent $40 billion on 300 new aircraft from Boeing and aims to transport 300 million passengers annually by 2034. Despite inflation, European consumers are prioritizing travel.

Portfolio Pulse from Upwallstreet

May 22, 2023 | 2:20 pm

F

SQM

SQM and Ford Motor Company have announced a long-term strategic agreement to secure the supply of high-quality lithium products for electric vehicle production. The agreement will ensure the supply of battery-grade lithium carbonate and lithium hydroxide, essential components for electric vehicle batteries.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 2:17 pm

NVO

A Mayo Clinic study found that Novo Nordisk's Wegovy (semaglutide) reduced the risk of heart disease and boosted weight loss. The risk of heart attack or stroke dropped to 6.3% from 7.6% after a year of taking the drug. More extensive studies are needed to confirm the long-term effects.

Portfolio Pulse from Vandana Singh

May 22, 2023 | 2:17 pm

NVO

Novo Nordisk announced positive results from the OASIS 1 trial, a phase 3a trial for oral semaglutide 50 mg in obesity treatment. The trial demonstrated a statistically significant weight loss of 15.1% compared to 2.4% with placebo. The company expects to file for regulatory approval in the US and EU in 2023.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 2:13 pm

AKBA

Akebia Therapeutics announced that the UK MHRA has approved Vafseo for the treatment of symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis. This news has led to an increase in Akebia's share price.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 2:11 pm

XOM

Exxon Mobil has purchased drilling rights to a large area of land in Arkansas for lithium production, a key ingredient in batteries for electric vehicles and electronics. The acquisition signals Exxon's preparation for a future less reliant on gasoline and diversifies its portfolio.

Portfolio Pulse from Akanksha Bakshi

May 22, 2023 | 2:07 pm

MBOT

Microbot Medical announced a 100% success rate for its LIBERTY system in a pre-clinical animal study conducted by leading European physicians, causing its shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 2:05 pm

IBM

IBM CEO Arvind Krishna stated on CNBC that many countries are investing in quantum technology, and quantum-safe encryption will become standard.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 1:48 pm